

## Erelzi<sup>™</sup> (etanercept-szzs) – Indication removals

- On January 26, 2018, the <u>FDA approved</u> the deletion of two indications and related information from Sandoz's <u>Erelzi (etanercept-szzs)</u> drug label:
  - For reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Erelzi can be used in combination with <u>methotrexate</u> (MTX) in patients who do not respond adequately to MTX alone.
  - For the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
  - The FDA has not concluded that these deletions are necessary for reasons of safety or efficacy.
- Erelzi is also indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years or older, and ankylosing spondylitis (AS).
- Enbrel® (etanercept), the reference product for biosimilar Erelzi, is indicated for the treatment of RA, polyarticular JIA in patients aged 2 years or older, PsA, AS, and PsO in patients 4 years of age and older.
- Erelzi carries a boxed warning for serious infections and malignancies.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.